147 related articles for article (PubMed ID: 33422398)
1. Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan.
Yeh KH; Yang TS; Hsu TC; Tzu-Liang Chen W; Chen HH; Teng HW; Lin BW; Kuan FC; Chiang FF; Duann CW; Li YS; Lin MT; Fiala-Buskies S; Ducreux M; Wang JY
J Formos Med Assoc; 2021 Nov; 120(11):2023-2031. PubMed ID: 33422398
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
4. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
Xu J; Xu RH; Qin S; Pan H; Bai Y; Chi Y; Wang L; Bi F; Cheng Y; Liu T; Ma D; Shen L; Ba Y; Liang J; Wang X; Yau TCC; Ma BB; Yeh KH; Lin JK; Kappeler C; Shapiro J; Kalmus J; Li J
J Gastroenterol Hepatol; 2020 Aug; 35(8):1307-1316. PubMed ID: 31900959
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
8. Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort.
Metges JP; Genet D; Tougeron D; Ligeza C; Ducreux M; Borg C; Guimbaud R; Phelip JM; Dourthe LM; Kim S
Future Oncol; 2021 Sep; 17(25):3343-3353. PubMed ID: 34011165
[No Abstract] [Full Text] [Related]
9. [Analysis of metastatic colorectal cancer patients treated with regorafenib in real-world practice].
Jiang ZC; Sun YK; Zhang W; Yang L; Cui CX; Wang HY; Zhang HG; Yihebali C; Zhou AP
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(26):2018-2022. PubMed ID: 32654446
[No Abstract] [Full Text] [Related]
10. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
11. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
Carrato A; Benavides M; Massutí B; Ferreiro-Monteagudo R; García Alfonso P; Falcó E; Reboredo M; Cano T; Gallego J; Viéitez JM; Layos L; Salud A; Polo E; Dotor E; Durán-Ogalla G; Rodriguez-Garrote M; Calvo A; Grande E; Aranda E
BMC Cancer; 2019 Jun; 19(1):533. PubMed ID: 31159765
[TBL] [Abstract][Full Text] [Related]
12. Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer.
Kato T; Kudo T; Kagawa Y; Murata K; Ota H; Noura S; Hasegawa J; Tamagawa H; Ohta K; Ikenaga M; Miyazaki S; Komori T; Uemura M; Nishimura J; Hata T; Matsuda C; Satoh T; Mizushima T; Ohno Y; Yamamoto H; Doki Y; Eguchi H
Sci Rep; 2023 Feb; 13(1):2331. PubMed ID: 36759648
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study.
Kim JH; Kim SY; Kim KP; Kim TW; Chae SY; Kim HJ; Kim JS; Ryu JS; Moon DH; Kim JE; Hong YS
Target Oncol; 2019 Dec; 14(6):689-697. PubMed ID: 31555963
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
[TBL] [Abstract][Full Text] [Related]
15. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY
Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912
[TBL] [Abstract][Full Text] [Related]
18. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T; Yamaguchi K; Sugimoto Y; Hama T
Oncol Res; 2019 May; 27(5):551-556. PubMed ID: 29914591
[TBL] [Abstract][Full Text] [Related]
20. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
